DENVER--(BUSINESS WIRE)--TranS1®, a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine, has named Chris Groppa to the position of chief marketing officer and director of reimbursement.
In this role, Groppa will oversee the development and implementation of all marketing activities and will continue to oversee TranS1’s insurance reimbursement strategy. He brings more than a decade of digital marketing, communications and product development expertise to the TranS1 team. His prior experience includes product development work with Blue Cross Blue Shield Association, brand marketing for IBM, as well as extensive marketing communications agency experience. He received his Bachelor’s Degree from the University of Wisconsin-Madison and a Master of Business Administration from the University of Notre Dame.
“AxiaLIF can truly change people’s lives for the better, and the opportunity to work on such a special product is very exciting,” said Groppa. “I’m also thrilled to be located in the heart of Denver, one of the most dynamic health-tech markets in the country, and the ideal place to build our business.”
TranS1 develops and supports a product line that provides a foundation for living well, driven by surgeon innovation. The company’s flagship product, AxiaLIF®, offers surgeons and patients a minimally invasive alternative for fusion at the L5-S1 joint. Peer-reviewed medical studies report that AxiaLIF® patients experience reduced pain and blood loss, shorter hospital stays and faster recovery times compared to traditional approaches to L5-S1 fusion*.
“Chris brings a fresh perspective to TranS1. His extensive marketing experience and work in the insurance industry is a huge asset to our company. We look forward to supporting him as he does great things at TranS1,” said Jeff Schell, TranS1's president and CEO.
TranS1 is a medical device company that develops and supports surgeon-driven innovations for spinal fusion. TranS1’s flagship product, AxiaLIF, offers surgeons and patients a minimally invasive option for spinal fusion at the L5-S1 joint using a pre-sacral approach. As demonstrated by the CPT Editorial Board awarding AxiaLIF with a Category One CPT Code (22586), the AMA has determined that AxiaLIF is a procedure that is consistent with contemporary medical practice and is widely performed*. More than 14,000 AxiaLIF procedures have been performed in the United States alone, and the medical community has responded with more than 75 peer-reviewed studies that demonstrate substantial evidence of the safety, efficacy, and positive long-term outcomes of AxiaLIF. TranS1 is based in Denver, Colorado. For more information, please visit www.TranS1.com.
* Gundanna MI, Miller LE, Block JE. Complications with axial presacral
lumbar interbody fusion: A 5-year postmarketing surveillance experience. SAS
Mistry AM, Godil SS, Parker SL, McGirt MJ. Axial presacral lumbar interbody fusion: a systematic literature review. J Manag Care Med. 2014;17(3):47-56.
Tobler WD, Gerszten PC, Bradley WD, Raley TJ, Nasca RJ, Block JE. Minimally invasive axial presacral L5-S1 interbody fusion: two-year clinical and radiographic outcomes. Spine (Phila Pa 1976). 2011;36(20):E1296-1301.